anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
There is substantial data to suggest that EGFR and Her-2/neu expressions are important predictors for prognosis in HNSCC. EGFR blockade with a monoclonal antibody in conjunction with radiotherapy has been shown to improve survival over radiotherapy alone in patients with locally advanced HNSCC. Dual inhibition of EGFR and ErbB2 tyrosine kinases results in greater inhibitory effect of the downstream signaling pathways in cancer cells than inhibition of either receptor alone. Phase I studies in HNSCC suggested that the drug is well tolerated when delivered either alone or concurrently with cisplatin based chemoradiotherapy in HNSCC.

We propose to combine lapatinib with RT alone in patients with locally advanced HNSCC who cannot tolerate chemotherapy. The main objective of the study is to determine the efficacy of combining concurrent radiation and lapatinib in terms of time-to-progression (TTP) in this group of patients. In addition, we will determine the 2-year locoregional control rate (LRC), progression-free survival (PFS) and overall survival (OS) in these patients. We will also evaluate the profile and frequency of late toxicity, specifically mucosal and dermatologic toxicity, of the combination of lapatinib and RT in patients with locally advanced HNSCC.
The invention discloses recombinant protein encoded by tilapia lake virus S8 gene and application thereof. The amino acid sequence of the recombinant protein is shown as SEQ ID NO. 2, and the nucleic acid base sequence for coding the protein is shown as SEQ ID NO. 1. The recombinant protein obtained by the invention has better immunogenicity, can induce immune animals to generate specific antibodies with higher titer, has stronger virus neutralization activity, can neutralize viruses to ensure the viruses to be infectious, and can be used as a therapeutic drug for tilapia lake virus diseases. Therefore, the tilapia lake virus S8 gene and the encoding protein thereof have important significance for developing novel tilapia lake virus disease vaccines, immunological detection kits and treatment products, and provide an effective solution for tilapia lake virus diseases.
The invention is thatDiscloses a series of PROTAC polypeptides with an amino acid general formula (1) for targeted degradation of DDX24 protein, and the specific sequence is as follows: (1) R1-Ahx linker-E3 ligand-R2. Wherein R1 is a polypeptide which is targeted to bind to DDX24 protein and comprises TVCTWYCYCAAYQRA or LT (p) FEHYWAQLTS (p), the linker is an amino acid connecting part which is represented by Ahx and comprises a branched or unbranched, cyclic or acyclic, saturated or unsaturated chain of 6 carbon atoms, and the E3 ligand is A Ligand (ALAPYIP) of ubiquitin ligase VHL. R2 is a cell penetrating peptide comprising R D RR D RR D RRR or RRRRRRRR. (R D  refers to D-configuration arginine and R refers to L-configuration arginine). The present specification relates generally to compounds having the general formula (1) wherein R1, R2 are any one of the meanings defined herein, and pharmaceutically acceptable salts thereof. The specification also relates to the use of such chimeras and pharmaceutically acceptable salts thereof in the treatment of human or animal tumors. The present specification also relates to processes and intermediate compounds involved in the preparation of such chimeras, and to pharmaceutical compositions containing such compounds.
All patients in this study will receive ofatumumab and bendamustine as an IV infusion for 6 cycles (a cycle is defined as 21 days in length). Patients will receive as an IV infusion of bendamustine Days 1 and 2 of Cycles 1-6, ofatumumab Days 1 and 8 during Cycle 1 only and on Day 1 of Cycles 2-6.
Opium Tincture, USP (Deodorized), is for oral administration. It is freed from unpleasant odor or nauseating substances by “denarcotization” with a petroleum distillate. Opium tincture is a clear, reddish-brown hydroalcoholic solution.

Each 100 mL contains 1 g of anhydrous morphine (represents the equivalent of 10 g of Powdered Opium, USP), alcohol, 19%, and water.

Opium has a very characteristic odor and a very bitter taste. The opiates are the most effective and prompt-acting nonspecific antidiarrheal agents.
Vascular dementia (VaD) is a clinical syndrome of acquired intellectual and functional impairment that results from cerebrovascular diseases. SaiLuoTong capsule is a traditional Chinese medicine compound; it is composed of ginseng extract (the main composition: ginseng total saponins), ginkgo biloba extract (the main composition: YinXingTong ester) and safflower extract (the main composition: the west safflower total glycosides). The function of SaiLuoTong capsule is Yiqi Huoxue and Huayu Tongluo in Chinese traditional medicine theory. Pharmacodynamics studies showed that SaiLuoTong capsule can significantly improve neurological symptoms caused by focal cerebral ischemia in animals, and learning and memory ability in animal models of VaD. The result of the phase II study showed that the efficacy of SaiLuoTong capsule in the treatment of patients with VaD was better than that of placebo group and no difference in safety. Based on these previous evidences, the investigators conduct this study to further confirm the efficacy and safety of SaiLuoTong capsule in patients with mild to moderate VaD. This study is a phase III clinical trial of SaiLuoTong capsule for treatment of vascular dementia. The study is a 52-week, multicentre, randomized, double -blind, placebo-controlled study.
Adolescents with Down syndrome will participate in an eight-week, center-based exercise intervention. Participants will undergo an hour of exercise intervention each week. During this time, participants will be working with a team consisting of a physician, physical therapy student volunteers, and clinical research coordinators. Exercises will focus on strength and endurance of all major muscle groups, while ensuring proper technique and form is used. They will also receive instruction on how to continue the exercise program at home.

Prior to starting, and at the end of eight sessions, all exercise participants will undergo testing procedures for anthropometric, strength and flexibility measurements. This data will be collected as part of clinically evaluating the impact of the program on each participant. In addition to the exercise program (and clinical assessments of fitness), DSFit participants will complete study measures of behavioral functioning as well as scales of depression and anxiety. Participants in the DSFit study will also complete a weekly exercise log during the intervention and for a follow-up period afterwards.
We describe a unique case of 27-year-old male with Gitelman syndrome (GS) co-exist with pseudohypoparathyroidism type 1B (PHP1B). The patient presented with a 5-year history of seizures, tetany, and numbness of the extremities. Further examinations showed recurrent hypokalemia, inappropriate kaliuresis, hypocalcemia, hyperphosphatemia, and elevated PTH levels. A novel variant of autosomal recessive GS (p.Val287Met SLC12A3) and a novel 492.3Kb deletion containing the whole of STX16, were discovered by a whole-exome sequencing. Following the diagnosis, calcitriol, calcium, and potassium supplements were started. Hematuria calcium and phosphorus levels, as well as blood potassium levels, have recovered and remained within normal ranges after 3 years of follow-up. Our findings have important consequences for supporting the idea that heterozygosity for variants have effects on the patients' clinical performance with autosomal recessive inheritance disorders. Further study is need for the putative effects of the variant. Likewise, further investigation with regards to the gene-gene interaction relations between GS and other electrolyte imbalance disorders is warranted.
This study examined the effect of online nursing education given to women diagnosed with gynecological cancer and receiving chemotherapy. This randomized controlled experimental study was conducted in a public hospital in Balıkesir province between December 1, 2021 and June 1, 2024. The study sample consisted of 90 women (intervention=45, control=45). Online nursing education was given to women in the intervention group receiving chemotherapy. Patients in the control group received routine nursing care. The study used the women's descriptive characteristics questionnaire, disease and treatment questionnaire, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Nightingale Symptom Assessment Scale, nurse follow-up form and patient satisfaction questionnaire. Data were collected during three chemotherapy cycles in four phases.
This application presents a method and logic engine for personalized dosing of food and nutrients to enhance an individual's overall well-being. The method involves collecting comprehensive data, including medical records, nutritional habits, and individual traits. Utilizing AI algorithms, the system analyzes the data in conjunction with external criteria, establishing optimal dosing parameters. The logic engine employs techniques such as K-nearest neighbor analysis and expert rules to determine precise dosages that maximize therapeutic effects while minimizing adverse outcomes. The system generates practitioner-readable reports and can interface with medical devices for dose administration. Additionally, a personalized health assessment system adapts nutrition plans based on real-time data and user feedback. A dedicated social support platform encourages engagement and information exchange among users with similar health conditions.
Patients receive yttrium Y 90 glass microspheres via a catheter over 5 minutes on day 0. Patients may receive additional treatments at 4-12 week intervals until all tumors in the liver have been treated in the absence of disease progression or unacceptable toxicity.
After Helicobacter pylori drug resistance mutation gene detection, according to genotypic antibiotic resistance pattern of each one, give esomeprazole 20mg bid and bismuth potassium citrate 0.6 g bid, combined two sensitive antibiotics of Amoxicillin, tetracycline,clarithromycin, metronidazole,and levofloxacin. All regimens will be given for 14 days.
The attention control condition consists of 8 weekly telephone calls with a study interventionist. Sessions will occur via scheduled telephone calls and follow a structured procedure. Telephone calls are designed to monitor symptoms and overall wellness. Each week, participants will be asked about current symptoms, flare patterns, and physical and emotional wellbeing.
The 'double burden of malnutrition' is a global health challenge that increasingly affects populations in both low- and middle-income countries (LMICs). This phenomenon refers to the coexistence of undernutrition and overweight or obesity, as well as other diet-related non-communicable diseases, in the same population, household or even individual. While noteworthy progress has been made in reducing undernutrition in some parts of the world, in many of these areas, the prevalence of overweight and obesity is increasing, particularly in urban areas, resulting in greater numbers of people who were undernourished in childhood and have overweight or obesity in adulthood. This creates a complex and challenging situation for research experts and policymakers who must simultaneously address the public health burdens of undernutrition and overweight/obesity. This review identifies key challenges and limitations in the current research on the double burden of malnutrition in individuals, including the need for a more comprehensive and nuanced understanding of the drivers of malnutrition, the importance of context-specific interventions and the need for greater attention to the food environment and food systems. We advocate for the re-evaluation of research strategies and focus, with a greater emphasis on multidisciplinary and systems approaches and greater attention to the synergistic relationship between the biological, environmental, commercial and socio-economic determinants of malnutrition. Addressing these key challenges can enable us to better comprehend and tackle the multifaceted and dynamic issues of the double burden of malnutrition, particularly in individuals and work towards more effective and sustainable solutions.
Patients receive 3 doses of oral sildenafil citrate on 3 separate occasions at least 48 hours apart monthly for 18 months. Patients on all three arms will have undergone robotic-assisted laparoscopic surgery. All patients will take part in the questionnaire administration and quality-of-life assessments.
To determine a tendency to fever based on a normal temperature.SOLUTION: An acquisition part 111 acquires body temperature data representing a user's body temperature input in a user terminal 2. A determination part 112 calculates a normal temperature of the user based on a plurality of pieces of registered body temperature data and determines a temperature range for determining a tendency to fever of the user based on a threshold group stored in a threshold DB 123. The determination part 112 determines whether an acquired one body temperature datum is within the temperature range or not. A generation part 113 generates fever tendency information representing a tendency to fever when the number of pieces of body temperature data input within a first period necessary for calculating the normal temperature is equal to or more than the number of unknown determination data. When the above number is less than the number of unknown determination data, the generation part 113 generates indeterminable information representing that it is not possible to determine the tendency to fever of the user. A transmission part 114 transmits the information generated by the generation part 113 to the user terminal 2.SELECTED DRAWING: Figure 9
Periodontal disease is characterized by inflammation and bone loss. Central to its pathogenesis is the dysregulated inflammatory response, complicating regenerative therapies. Mesenchymal stem cells (MSCs) hold significant promise in tissue repair and regeneration. This study investigated the effects of specialized pro-resolving mediators (SPMs), Resolvin E1 (RvE1) and Maresin 1 (MaR1), on the osteogenic differentiation of human bone marrow-derived MSCs under inflammatory conditions. The stem cells were treated with SPMs in the presence of lipopolysaccharide (LPS) to simulate an inflammatory environment. Osteogenic differentiation was assessed through alkaline phosphatase activity and alizarin red staining. Proteomic analysis was conducted to characterize the protein expression profile changes, focusing on proteins related to osteogenesis and osteoclastogenesis. Treatment with RvE1 and MaR1, both individually and in combination, significantly enhanced calcified deposit formation. Proteomic analysis revealed the differential expression of proteins associated with osteogenesis and osteoclastogenesis, highlighting the modulatory impact of SPMs on bone metabolism. RvE1 and MaR1 promote osteogenic differentiation of hBMMSCs in an inflammatory environment, with their combined application yielding synergistic effects. This study provides insights into the therapeutic potential of SPMs in enhancing bone regeneration, suggesting a promising avenue for developing regenerative therapies for periodontal disease and other conditions characterized by inflammation-induced bone loss.
Hamstring Muscle Tightness is a common musculoskeletal condition that affects a significant proportion of the general population, particularly among collegiate students. Among the student population, sitting for longer periods during college hours is the primary cause of HMT. Evidence suggests that stretching with a combination of manual or instrument-assisted soft tissue mobilization are effective in improving hamstring muscle flexibility among individuals with HMT. A meta-analysis demonstrated a significant improvement in knee extension ROM and straight leg raise test measures following neural mobilization treatment which support the effectiveness of neural mobilization treatment in enhancing hamstring flexibility compared to muscle inhibition and stretching techniques . Especially, neural glides and neural stretching designed to restore the overall balance in the nervous system and can increase hamstring muscle flexibility, making them valuable interventions for individuals with HMT. A study on hamstring muscle flexibility in relation leg rotation suggest that hamstring stretching is enhancing the leg rotation and hamstring lengthening. Thus, dynamic stretching targeting the nerves and muscles is warranted for the treatment of tight hamstring in the general population, especially among collegiate students. This evidence provides input for the modification of dynamic sciatic nerve stretching to improve the effects of therapeutic interventions that focus on neuromuscular flexibility, joint ROM, and pain relief. Further evidence also suggests that nerve-directed stretching is superior to muscle-directed stretching in improving hamstring tightness in healthy adults. However, the role of nerve-directed dynamic stretching with hip rotation has not been addressed by previous interventional studies. Therefore, This study compared the effects of modified sciatic-nerve mobility exercises over dynamic hamstring muscle stretching on improving the hamstring length in collegiate students with HMT to determine the most effective approach for managing this condition.
Postural stability will be evaluated by a Prokin brand balance device (ProKin, Tecnobody, Bergamo, Italy), a force platform. After the tests are explained to the patients, the physical characteristics of the patients (age, height, body weight) will be recorded on the device and the device will be calibrated. The patients' feet will be placed naked on the platform with reference to the lines on the x and y axis. During the test, the arms will be in free position near the body. The tests will be performed on both feet with both eyes open and eyes closed. Each test will last 30 seconds. After each test has been completed, the device will be recalibrated. As a result of the tests, the ellipse area (mm2) and perimeter (mm) parameters will be recorded for statistical analysis. In addition, the patient's stability limits will be calculated as a percentage.
Atrial fibrillation, a prevalent type of arrhythmia, is increasingly contributing to the economic burden on healthcare systems. The development of innovative treatments, notably catheter ablation, has demonstrated both impressive and promising outcomes. However, these treatments have not yet fully replaced pharmaceutical approaches, primarily due to the relatively high incidence of atrial fibrillation recurrence post-procedure. Recent insights into endothelial dysfunction have shed light on its role in both the onset and progression of atrial fibrillation. This emerging understanding suggests that endothelial function might significantly influence the effectiveness of catheter ablation. Consequently, a deeper exploration into endothelial dynamics could potentially elevate the status of catheter ablation, positioning it as a primary treatment option for atrial fibrillation.
Atherosclerosis is an inflammatory disorder responsible for cardiovascular disease. Reactivation of efferocytosis, the phagocytic removal of cells by macrophages, has emerged as a translational target for atherosclerosis. Systemic blockade of the key 'don't-eat-me' molecule, CD47, triggers the engulfment of apoptotic vascular tissue and potently reduces plaque burden. However, it also induces red blood cell clearance, leading to anemia. To overcome this, we previously developed a macrophage-specific nanotherapy loaded with a chemical inhibitor that promotes efferocytosis. Because it was found to be safe and effective in murine studies, we aimed to advance our nanoparticle into a porcine model of atherosclerosis. Here, we demonstrate that production can be scaled without impairing nanoparticle function. At an early stage of disease, we find our nanotherapy reduces apoptotic cell accumulation and inflammation in the atherosclerotic lesion. Notably, this therapy does not induce anemia, highlighting the translational potential of targeted macrophage checkpoint inhibitors.
The study comprises a Phase 2 vaccination study and a Phase 2b challenge study. The primary objectives of the Phase 2 vaccination study are: 1. To evaluate, in healthy volunteers, the safety and clinical acceptability of three spaced doses (one month apart) of an investigational, live, oral, attenuated vaccine called CVD 1208S, with particular attention to the occurence of diarrhea, dysentery, and fever, and 2. To characterize immune responses following ingestion of this vaccine. The primary objective of the Phase 2b challenge study is to measure the protective efficacy of 3 spaced doses of vaccine after ingestion of an oral challenge strain called Shigella flexneri 2a strain 2457T.

Shigella is a leading cause of disease and death among children younger than 5 years living in developing countries. The difficulty controlling this infection has led experts to believe that prevention with the use of a vaccine is a promising strategy. At the CVD, we have pursued an approach of developing an oral, attenuated Shigella vaccine that prevents infection with the Shigella types of greatest clinical and epidemiologic importance. One of the strains to be included in the vaccine is called Shigella flexneri 2a. Investigators at the CVD have created a vaccine from Shigella flexneri 2a, designated CVD 1208S, using molecular biology techniques. To date, nearly 40 subjects have received varying doses of this vaccine with good clinical tolerance and modest immunogenicity. Previously a single dose of vaccine was used. In the current study, we will administer doses of vaccine on days 0, 28, and 56 to attempt to maximize immunogenicity. Approximately one month after the 3rd dose, a group of \~15-20 vaccinated volunteers along with a similar number of unvaccinated control subjects will be admitted to the CVD Research Isolation Ward at SNBL and challenged with wild type Shigella flexneri 2a. By comparing the attack rate of illness in vaccinated vs. unvaccinated subjects, we will determine the vaccine's ability to confer protective immunity.
Conformity: Age 60-85 years old; meet DSM-5 diagnostic criteria for major depressive disorder; currently in acute phase, HDRS-17 ≥ 24; history of suicide attempt in this depressive episode; current suicidal ideation, SIOSS ≥ 12.Exclusions: Patients with unstable physical diseases; patients currently suffering from acute inflammatory infection or chronic inflammatory disease; participated in another interventional clinical study within the past 1 month; previous or current diagnosis of other psychiatric diseases by DSM-IV ; abuse of alcohol and active drugs within 12 months, except for nicotine; severe aphasia, visual and hearing impairment, etc. unable to complete the scale evaluation; MECT treatment contraindications; pregnant, lactating women or planning pregnancy; allergic to propofol and succinylcholine chloride.
PURPOSE:To obtain an antifungal agent, having excellent effects even on patients with weakened immunological functions and high safety and useful for treating dermatomycosis, visceral mycosis, etc. CONSTITUTION:Thus compound of formula I (R<1> and R<2> are each a halogen or H; R<3> is H or a lower alkyl; 5 and m are each O or 1; A is N or CH; W is an aromatic ring or its condensed ring which may have one or more substituent groups or hetero-atoms such as N, S and O; X is a (substituted)alkanediyl, a (substituted)alkenedilyl, etc.; Y is S, >SO, >SO2, etc.; Z is H, halogen, lower alkyl, etc., except when W is thiazole ring; R<3> is methyl and A is H when r and m are each 0] or its acid addition salt, e.g. a compound of formula II. The compound of formula I is obtained by reacting a compound of formula III with a compound of formula TV (Hal is Br or Cl).